Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: Structures of abiraterone acetate ( 1 ), abiraterone ( 2 ), and galeterone ( 3 ).

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: Number of published papers by year from PubMed (results obtained using the “All” search field and keywords “abiraterone” ( A ) and “galeterone” ( C )) and Scopus (results obtained using the “Article title, Abstract, Keywords” field and keywords “abiraterone” ( B ) and “galeterone” ( D )).

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: Distribution of documents by type from Scopus (results obtained using keywords “abiraterone” or “galeterone” and the “Article title, Abstract, Keywords” field).

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: Distribution of documents by subject area from Scopus (results obtained using keywords “abiraterone” or “galeterone” and the “Article title, Abstract, Keywords” field).

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: VOSviewer generated an overlay visualization graph with the co-occurrence of keywords related to galeterone.

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques: Generated

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: Synthesis of galeterone ( 3 ) from dehydroepiandrosterone acetate ( 4 ). Reagents and conditions: (a) POCl 3 -DMF, CH 3 Cl, Ar, reflux; (b) benzimidazole, K 2 CO 3 , DMF, Ar, 80 °C; (c) 10% Pd on activated charcoal, PhCN, reflux; (d) 10% methanolic KOH, Ar, rt.

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques: Reflux

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: In vitro and in vivo metabolism of galeterone.

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques: In Vitro, In Vivo

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: Galeterone derivatives 26 – 33 .

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: C-3-modified derivatives of galeterone.

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques: Modification

Journal: Pharmaceutics

Article Title: Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

doi: 10.3390/pharmaceutics16111401

Figure Lengend Snippet: Structures of galeterone analogs 40 – 46 .

Article Snippet: These data enabled galeterone to be licensed to Tokai Pharmaceuticals Inc., Cambridge, MA, for further preclinical and clinical studies and granted it a new code name, TOK-001 [ ].

Techniques: